“We were contacted by physicians at Frankfurt University hospital on advice that they had an advanced-stage Ebola patient arrive at their hospital,” Joyce said. Aethlon had to seek special approval from the German regulatory authorities in order to ship the piece. “Hemotherapy was administered on day 12 after diagnosis and at that point in time he had multiple organ failure,” Joyce said. The patient was administered hemotherapy treatment for more than six hours and had no adverse effects. The physicians measured data points related to the treatment. The patient was monitored for changes in viral load, with the hope being for a reduction. Before treatment, the viral load was measured at 400,000 copies per milliliter for the Ebola virus. At the end of treatment physicians measured a reduction to only 1,000 copies per milliliter for Ebola. The patient is now free of the virus. The FDA has approved an investigational device exemption for the Hemopurifier, which the creators see as an advancement of feasible studies in relation to use of the device in the U.S.
Posted on: Sat, 15 Nov 2014 18:52:06 +0000